Company Description
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Benny Sorensen |
Contact Details
Address: 101 Main Street, Suite 1220 Cambridge, Massachusetts 02142 United States | |
| Phone | (617) 553-3952 |
| Website | hemab.com |
Stock Details
| Ticker Symbol | COAG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002114044 |
| CUSIP Number | 423494103 |
| ISIN Number | US4234941031 |
| Employer ID | 41-4241952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Benny Sørensen, M.D., Ph.D | President and Chief Executive Officer, Director |
| Mads Behrndt, M.Sc | Chief Financial Officer and General Manager |
| Catherine Madigan, M.D | Chief Medical Officer |
| Ananthram Murthy, Ph.D., M.Sc. | Chief Operating Officer |
| John Maraganore, Ph.D. | Chair of the Board of Directors |
| Linda Bain | Director |
| Laura Tadvalkar, Ph.D. | Director |
| Akshay Vaishnaw, M.D., Ph.D | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2026 | 10-Q | Quarterly Report |
| May 21, 2026 | 8-K | Current Report |
| May 11, 2026 | SCHEDULE 13G | Filing |
| May 11, 2026 | SCHEDULE 13D | Filing |
| May 11, 2026 | 8-K | Current Report |
| May 8, 2026 | SCHEDULE 13G | Filing |
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2026 | 424B4 | Prospectus |
| Apr 30, 2026 | EFFECT | Notice of Effectiveness |